Table 1

Savings (vs. null scenario) as a result of implementing universal screening for GBS (NIS at 2010 price levels)
TREATMENT COSTS Marginal Risk-factor Universal Savings
Unit costs Screening Screening
Hospitalization
Fatal and non-fatal anaphylaxis 4,301 3,686 20,890
Fatality vs. non-GBS 1,997 2,347 968
Sepsis vs. non GBS 11,441 419,988 173,336
Meningitis & sepsis vs. non-GBS 14,710 59,998 24,762
Post-Hospital Care vs. non-GBS 2,130 89,393 36,894
575,412 256,851 318,561
LTC
Deafness 508,260 104,858 43,227
Severe Neuro 2,640,519 1,604,008 662,002
Moderate Neuro 1,281,790 828,425 341,906
Mild Neuro 316,180 216,369 89,299
2,753,659 908,003 1,617,175
Total Health Service Costs 2,775,870 1,136,483 1,935,737
Lifetime productivity losses 1,382,007 570,378 811,828
Total Societal Costs 4,711,077 1,963,713 2,747,365

Ginsberg et al.

Ginsberg et al. Israel Journal of Health Policy Research 2013 2:6   doi:10.1186/2045-4015-2-6

Open Data